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Background: Leishmaniasis is an important parasitic disease affecting millions worldwide. Human cutaneous
leishmaniasis (CL) is endemic in Rio de Janeiro, Brazil, where is caused by Leishmania braziliensis. The adaptive immune
response is accountable for the healing of CL and despite of key role of CD8+ T cells in this immune response little is
known about the CD8+ T lymphocytes frequencies, apoptosis and antigen-responsive CD8+ T lymphocytes of CL patients
during antimonial therapy.
Methods: Using flow cytometry, we examined total and effector CD8+ T cells from CL patients before (PBT), during
(PDT) and after (PAT) treatment for apoptosis and frequencies upon isolation and after in vitro L. braziliensis antigens
(LbAg)-stimulation culture. Besides, a correlation study between immunological findings and lesion size was done.
Results: PDT showed lower frequencies of total CD8+ T lymphocytes and higher levels of apoptosis of these cells,
which were also observed following LbAg-stimulation culture. Regarding effector CD8+ T cells, high frequencies were
observed in PDT, while lower frequencies were observed in PAT. Interestingly, PDT showed higher frequencies of
apoptotic-effector CD8+ T lymphocytes. Similar results were seen after in vitro antigenic-stimulation assays. Correlation
analysis showed that the greater the size of lesion, the smaller the frequency of effector CD8+ T lymphocytes in PDT
and PAT, as well as a positive correlation between apoptotic-effector CD8+ T cells frequency and lesion size of PDT.
Conclusions: Changes in effector CD8+ T–lymphocyte frequencies, during and after treatment, seem to represent a critical
stage to generate an efficient immune response and suggest that these cells would be evolved in the triggering or in the
resolution of lesion, under the influence of therapy. This hypothesis opens new perspectives to clarify controversial
statements about the protective or deleterious role of CD8+ T cells in the cure or aggravation of CL and the new approach
of evaluating patients during treatment proved to be of utmost importance for understanding the immune response in
the healing process of human CL.
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Leishmaniasis is a group of diseases caused by different
species of protozoan parasites from the genus Leishmania
and is ranked as the sixth major neglected tropical disease
in the world. In Brazil, American tegumentary leishmania-
sis (ATL) was registered in all states and is endemic in Rio
de Janeiro, where it is caused mainly by Leishmania
(Viannia) braziliensis, leading to a spectrum of clinical,
immunological and histopathological manifestations, ran-
ging from self-healing localized cutaneous leishmaniasis
(CL) to destructive mucosal leishmaniasis [1,2]. CL is the
most frequent clinical form of ATL and is characterized
by the presence of a skin ulcer, which heals spontaneously
or after antimonial therapy [2,3]. While spontaneous heal-
ing appears to be associated with natural resistance, the
immunological mechanisms of resistance have not been
clearly defined. It was shown that early treatment fails to
prevent ulcer formation in CL [4].
Despite the CD4+ T-cell-mediated immune response
play a pivotal role in the processes either for cure or aggra-
vation of the disease, some reports highlighted that CD8+
T lymphocytes may also play important role in the mecha-
nisms for cure of and resistance to Leishmania infection
[5-10]. Although the role of CD8+ T cells has been well
established in these studies, there is a controversial state-
ments about protective or deleterious function of effector
subpopulation which has not been elucidated so far
[7,11-17]. Previous researches have focused mostly on im-
mune responses during active phase and at the clinical
cure of disease, thus the investigation of immunological
patterns of patients during the antimonial therapy is crit-
ical for better understanding the establishment of path-
ology and for determine beneficial parameters of the
immune responses associated with clinical cure.
CD8+ T lymphocytes are functionally heterogeneous and
the involvement of effector, naïve and memory CD8+ T-cell
subsets has already been described in antitumor immune
responses [18]. It is well established that human-effector
CD8+ T cells have the CD45RA+CD27− phenotype and
these subset is thought to result from CD8+CD27+ precur-
sors in response to antigenic stimulation [19-22]. To date
there are few reports about the role of CD8+ T-cell subpop-
ulations in the modulation of CL immune response and
their functional activity should be better investigated.
Some authors have shown that apoptosis is involved
in modulation of the immune response and may be dir-
ectly related to the immunopathogenesis of some dis-
eases including leishmaniasis [7,23-26]. Our previous
results suggest that active disease and spontaneous cure
of CL patients have been associated with higher or
lower percentages of apoptotic CD8+ T cells, respect-
ively [7]. Nevertheless, the association between apop-
tosis and functionally-defined CD8+ T-lymphocyte
subsets in CL patients still remains undefined.The present study investigates frequency and apoptosis
of total and effector CD8+ T lymphocytes, in blood
smears from CL patients before, during and after treat-
ment, as well as evaluates antigen-specific effector CD8+
T-lymphocyte frequency and correlating immunological
features with lesion size.
Methods
Study Groups
All CL patients enrolled in this study live in Leishmania
braziliensis-endemic areas in Rio de Janeiro, Brazil [2]
and were recruited at Leishmaniasis Surveillance La-
boratory, Evandro Chagas Clinical Research Institute
(IPEC), Oswaldo Cruz Foundation (FIOCRUZ), Rio de
Janeiro, Brazil. All patients are volunteers and informed
consent was obtained from all individuals prior to col-
lection of blood samples. Diagnosis of leishmaniasis was
based on clinical, laboratorial and epidemiological cri-
teria. Ulcerated cutaneous lesions were associated with
positive Montenegro skin test (MST) and positive para-
sitological exams to confirm a diagnosis of CL. All pa-
tients were submitted to meglumine antimoniate
treatment according to the guidelines of the Brazilian
Ministry of Health and sub-divided in three cohorts: Pa-
tients before treatment (PBT, n = 8, 36 ± 9 years old),
evaluated after confirmed diagnosis and before begin-
ning of anti-Leishmania treatment; patients during
treatment (PDT, n = 14, 35.7 ± 13.4 years old), evaluated
at the tenth day after beginning anti-Leishmania treat-
ment, still showing ulcerated skin lesions; and patients
after treatment (PAT, n = 11, 41 ± 15,19 years old), at the
eighty day after the beginning of treatment. After treat-
ment, all patients presented clinical cure, which was de-
fined as full epithelialization of ulcerated lesions,
regression of crusts, desquamation and infiltration.
Healthy subjects (HS, n = 18, 29 ± 9.7 years old), from
non-endemic areas, showing neither previous history of
leishmaniasis nor any other co-morbidity, such as in-
flammatory diseases, diabetes or cardiologic disease,
was analyzed similarly. The duration of lesion ranged
from one month (less than 30 days) to six months and
the larger diameter measured of the ulcers varied from
15 to 60 mm (PBT: 40 ± 5.3 mm; PDT: 42 ± 12.5 mm;
PAT: 41.4 ± 13.9 mm). Basic demographic information
of the studied groups is summarized in Table 1.
Ethics statement
This study was approved by National Ethical Clearance
Committee of Brazil (CONEP) as well as by the Ethical
Committee for Human Research from Oswaldo Cruz
Foundation (CEP-FIOCRUZ) and Evandro Chagas Clinical
Research Institute (CEP-IPEC/FIOCRUZ), Brazil. All of
them adhere to the principles established in the Declar-
ation of Helsinki on human subject research. Written
Table 1 Demographic and clinical information of groups included in the study
HS PBT PDT PAT
Number of volunteers 18 8 14 11
Sex: M/F 11/7 7/1 9/5 8/3
Age 29 ± 9.7 36.1 ± 9 35.71 ± 13.4 41 ± 15.1
Number of lesions NA 1 1 1
Diameter of lesion (mm) (BF) NA 40 ± 5.3 42 ± 12.5 41.4 ± 13.9
Montenegro Skin Test (MST) (mm) (BF) NA 11.3 ± 1.8 11.7 ± 3.6 12.3 ± 3.6
Duration of disease (months) NA 2 (1–6) 2 (1–6) 2 (1–5)
Age; Diameter of lesions; and MST: mean ± Standard Deviation.
Duration of disease: median (range).
BF =measured Before Treatment.
NA = Not Applicable.
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Ex vivo and in vitro phenotypic and apoptotic assays
Heparinized venous blood was obtained from CL pa-
tients and HS and peripheral blood mononuclear cells
(PBMC) were obtained by Ficoll-Hypaque density gradi-
ent centrifugation (Sigma Aldrich, St. Louis, MO, USA)
separation. A fraction of these cells was stained ex vivo
and another was submitted to in vitro stimulation assay,
where PBMC were adjusted (3x105/well) in RPMI
medium supplemented with 10% of AB Rh+ inactivated
human serum (Sigma Aldrich) and then distributed in
triplicate in a 96-well, flat-bottomed plate (Becton Dick-
inson, San Jose, CA, USA), as described previously [27].
Cells were stimulated with particulate antigens of L. bra-
ziliensis (LbAg) (disrupted in repeated freeze/thaw cycles
and a final 5-minutes ultrasonication). Non-stimulated
and 1 μg/well-concanavalin A (ConA)-stimulated cells
(Sigma Aldrich) were used as negative and positive con-
trols of proliferation, respectively. Cultures were carried
out in a humidified atmosphere of 5% CO2 at 37°C. The
time of incubation of ConA-stimulated cells was three
days, while non-stimulated and LbAg-stimulated cells
were five days. After that, cells were harvested and pre-
pared for staining protocols.
Cell surface and apoptosis staining protocol
Staining protocol was performed as previously described
[7]. Briefly, ex vivo or in vitro assay’s cells were stained
for surface markers with a panel of monoclonal anti-
bodies, as follows: FITC-conjugated anti-CD3; APC-
conjugated anti-CD8; PECy7-conjugated anti-CD27;
ECD-conjugated anti-CD45 (all Beckman Coulter,
Miami, FL, USA) in PBS containing 0.1% sodium azide
(NaN3; Sigma Aldrich) and 2% fetal calf serum (Sigma
Aldrich) and incubated for 20 minutes on ice. After-
wards, these samples were incubated with 20 μg/mL of
7-aminoactinomycin D (7-AAD; Sigma Aldrich) for
30 minutes at 4°C, for apoptosis evaluation, as describedin elsewhere. The samples were kept on 7-AAD solution,
protected from light, until the flow cytometry acquisition.Flow cytometry
Fifty thousand-event acquisitions were performed on
Beckman Coulter Cyan ADP and on BD FACSAria II
flow cytometers. The limits for the quadrant markers
and histograms were always set based on non-staining
cells and isotypic controls and color compensations
were made based on simple labeling samples. A multi-
parameter flow cytometric protocol to determine the
frequencies of total and effector CD8+ T lymphocytes
and apoptosis was done in Kaluza 1.2 software (Beck-
man Coulter, Inc., Brea, CA, USA). In this manner, the
frequency of total CD8+ T lymphocytes was determined
in a CD3 vs. CD8 dot plot (Figure 1C) created from a
region encompassing lymphocyte population in a SSC
vs. FSC density plot (Figure 1A), excluding doublets
(Figure 1B). To evaluate the frequency of effector CD8+
T-lymphocyte subsets a CD27 vs. CD45RA dot plot
gated on CD3+CD8+ region was created and data
CD27+CD45RA− was recorded (Figure 1D; Q − +).
Simultaneously, for apoptosis determination in total
(Figure 1E) and effector (Figure 1F) CD8+ T cells a FSC
vs. 7AAD dot plot was created gated on dot plots repre-
sented in Figure 1C and Figure 1D, respectively.Statistical analysis
For statistical analyses between two groups at a time,
Mann–Whitney U test was used. For comparison between
nonstimulated and stimulated CD8+ T-lymphocyte sub-
sets, we used a paired nonparametric Wilcoxon test. These
results were reported as mean ± standard error (SEM). We
also used a Spearman’s rank correlation test. Correlations
and intergroup differences were considered statistically
significant when P < 0.05. All statistical calculations and
graphical representations of data were obtained using the
GraphPad Prism version 5.0 software (GraphPad Software
Inc., La Jolla, CA, USA).
Figure 1 Representative flow cytometry protocol to determine the frequencies of CD8+ T-lymphocyte subsets and apoptosis. Peripheral blood
mononuclear cells (PBMC) from cutaneous leishmaniasis patients were stained ex vivo and after antigenic-stimulated cultures with CD3-FITC, CD8-APC,
CD45RA-ECD, CD27-PE-Cy7 and 7-AAD. The lymphocytes were gated on forward (FSC) vs side (SSC) scatter dot-plot (A), backgated from CD3+ histogram
and doublets were excluded by a density plot of FSC Area vs FSC Width (B). CD27 vs CD45RA dot plot (D) gated on CD3+CD8+ region (C) was used to define
the frequencies of effector and naïve CD8+ T lymphocytes. Frequency of apoptotic cells (7AADlow) was determined by FSC vs 7AAD dot-plot gated on
CD3+CD8+ cells (total CD8+ T lymphocytes) (E) and on CD45RA+CD27neg cells (effector CD8+ T lymphocytes) (F).
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Frequency of total and effector CD8+ T cells
We performed comparative analysis of the frequency of
total CD8+ T cells from patients before treatment (PBT),
patients during treatment (PDT) and patients after treat-
ment (PAT), as well healthy subjects (HS). The mean
frequency of total CD8+ T cells was significantly lower in
PDT (15.3 ± 1.5) compared to PBT (23 ± 2; P < 0.05) and
to HS (23.6 ± 1.2; P < 0.001). These lower frequency also
were seen when comparing PDT with in PAT (21.5 ± 1.6;
P = 0.07), although these difference was not statistically
significant (Figure 2A).
Due to the heterogeneity of the peripheral CD8+ T-cell
pool, we performed a dichotomized analysis in order to
discriminate the differential distribution of their subsets.
Thus, in order to highlight the importance of effector
CD8+ T lymphocytes in the parasitic immune responses,
we analyzed the CD8+CD45RA+CD27− T cells, an effectorphenotype. We observed a higher frequency of these cells
in PDT (31.2 ± 2.2) compared to other three groups, HS
(12 ± 1.4; P < 0.001), PBT (25 ± 2.7; P < 0.05) and PAT
(16.9 ± 2.7; P < 0.001) (Figure 2B). PBT also showed higher
frequency of these cells when compared to HS and PAT. It
is important to note that PBT and PDT showed lower per-
centages of CD8+CD45RA+CD27+ naïve T-cell subset
when compared to HS and to PAT, which could be a con-
sequence of differentiation of naïve in effector CD8+ T
cells, during active disease (data not shown).
Apoptosis of total and effector CD8+ T cells
Previous report of our group showed that there was a higher
rate of apoptotic-total CD8+-T lymphocytes in non-healing
lesions of CL when compared to lesions that progress to
spontaneous cure [7], suggesting a modulate role of apop-
tosis on these cells in CL lesion environment. Following this
hypothesis, we investigated the role of apoptosis in blood
Figure 2 Ex vivo analysis of total CD8+ T-lymphocyte frequency and apoptosis in human cutaneous leishmaniasis. (A) Total CD8+ T lymphocytes;
(B) Effector CD8+ T lymphocytes; (C) Apoptotic-total CD8+ T lymphocytes; (D) Apoptotic-effector CD8+ T lymphocytes. HS - healthy subjects (n = 18);
PBT – patients before treatment (n = 8); PDT - patients during treatment (n = 14); PAT - patients after treatment (n = 11). Statistical analyses were performed
by Mann Whitney Test. The bars represent the mean± standard error. Results were considered significant with P< 0.05 - *(P < 0.05) **(P < 0.01) ***(P< 0.001).
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etry. The results of ex vivo analyses showed higher frequen-
cies of apoptotic-total (14.9 ± 2.8) and apoptotic-effector
CD8+ T cells from PDT (18.6 ± 2.8) when compared to:
PBT (apoptotic-total, 2 ± 0.6; P < 0.001; apoptotic-effector,
2.3 ± 1.4; P < 0.001); PAT (apoptotic-total, 6.2 ± 1.7; P < 0.05;
apoptotic-effector, 4.3 ± 1.5; P < 0.001); and HS (apoptotic-
total, 1.8 ± 0.4; P < 0.001; apoptotic-effector, 0.4 ± 0.2; P<
0.001) (Figure 2C and D). These results showed pronounced
percentages of apoptotic CD8+ T lymphocytes only on pa-
tients during treatment, which tend to decrease after the
end of treatment indicating that this phenomenon could be
associated to the glucantime therapy and the immune re-
sponse triggering.
Leishmania braziliensis-reactive CD8+ T lymphocytes
In order to determine an expansion of CD8+ T cells in-
volved in a specific anti-Leishmania T-cell response,
PBMC were cultured in the absence and in the presence
of L. braziliensis antigens (LbAg). Frequencies of LbAg-
reactive-total CD8+ T cells were compared among the fourstudied groups. PDT showed lower mean frequencies
of Leishmania braziliensis-reactive CD8+ T lymphocytes
(13.8 ± 1.0) when compared to PAT (24.7 ± 3.9; P< 0.05)
(Figure 3A); to HS (20.2 ± 1.6; P < 0.01); and to PBT (17.5 ±
2.5), although the difference between the frequencies of PBT
and PDTwas not statistically significant (P = 0.2) (Figure 3A).
To evaluate the modulation in the frequencies of LbAg-
reactive CD8+-T cells, we performed paired analyses be-
tween the percentage of nonstimulated-total CD8+ T cells
(background - BG) and those of LbAg-stimulated CD8+ T
cells. Both PBT (BG, 21.4 ± 2.8; LbAg, 17.5 ± 2.5; P< 0.05)
and PDT (BG, 16.9 ± 1; LbAg, 13.8 ± 1; P < 0.01) showed
lower frequencies of LbAg-reactive total CD8+ T cells, more
pronounced in PDT (Figure 3C and D, respectively). On the
other hand, PAT showed a higher frequency of these cells
(BG – 17.7 ± 3.7; LbAg – 24.7 ± 3.9; P < 0.05) (Figure 3E),
showing that LbAg down-modulate CD8+ T cells during
in vitro assays with cells obtained from PBT and PDT. In
the opposite manner, LbAg up-modulate these cells in as-
says performed with cells from patients after treatment and
clinical cure. No changes on frequency of these cells were
Figure 3 In vitro analyses of total (A – E) and apoptotic (F – J) CD8+ T-lymphocyte frequency. (A and F): comparison among the percentages of
Leishmania braziliensis antigen (LbAg)-stimulated cells from HS - healthy subjects (n = 8); PBT – patients before treatment (n = 8); PDT - patients during
treatment (n = 11); and PAT - patients after treatment (n = 6). Statistical analyses were performed by Mann Whitney Test and the bars represent the mean±
standard error. (B, C, D, E, G, H, I, J): comparison between stimulated (Lb-Ag) and nonstimulated cells (BG – background) from HS; PBT; PDT and PAT,
respectively. Solid lines connect the results for the same individual. Statistical analyses were performed by paired, nonparametric Wilcoxon test. Results were
considered significant with P < 0.05. *(P < 0.05) **(P < 0.01) ***(P < 0.001).
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LbAg, 20.2 ± 1.6) (Figure 3B).
Corroborating the results showed in ex vivo findings, we
observed higher rates of apoptotic-CD8+ T cell in cultures
with LbAg-stimulated cells from PDT (12.8 ± 1.5) compared
to PBT (4.9 ± 0.6; P < 0.01); PAT (2.9 ± 0.8; P < 0.01); and HS
(5.2 ± 1.2; P < 0.001) (Figure 3F). The paired analysis con-
firmed that the higher frequency of apoptotic-total CD8+ T
lymphocytes from PDT (BG, 6.4 ± 1.5; LbAg, 12.8 ± 1.5; P <
0.001) is antigen-dependent (Figure 3I), and could not be
seen in HS- (BG, 3.7 ± 0.7; LbAg, 5.2 ± 1.2), in PBT- (BG,
5.6 ± 0.9; LbAg, 4.9 ± 0.6) neither in PAT-in vitro experi-
ments (BG, 2.7 ± 0.6; LbAg, 2.9 ± 0.8) (Figure 3G, H and J,
respectively).
Regarding frequency of LbAg-reactive-effector CD8+ T
cells during in vitro assays, it was observed higher frequen-
cies of these cells in experiments with cells from PDT (41.8
± 3.1) and from PAT (35.8 ± 4.6) when compared to experi-
ments with cells from PBT (15.9 ± 1.3; P< 0.01) and also to
HS (13.4 ± 1.3; P< 0.01 and P < 0.001) (Figure 4A). The
modulation of frequency of these cells in the presence of
these antigens was confirmed by the paired test in which we
detected higher frequencies in PDT (BG, 33.1 ± 4; LbAg,
41.8 ± 3.1; P< 0.001) and PAT (BG, 29.8 ± 4.3; LbAg, 35.8 ±
4.6; P< 0.05) (Figure 4D and E, respectively), while PBT
(BG, 14.6 ± 1.5; LbAg, 15.9 ± 1.3; P< 0.01) and HS showed
similar frequencies among stimulated and nonstimulated
cells (BG, 11.3 ± 0.7; LbAg, 13.4 ± 1.3) (Figure 4C and B,
respectively).
Concerning the apoptotic-effector CD8+ T cells, a com-
parison among the four studied groups showed higherpercentages in PDT (28.1 ± 1.5) when compared to HS (3 ±
1.1, P < 0.001) and PBT (3.8 ± 0.7, P < 0.01). We also
observed higher frequencies in PAT (12.3 ± 1.1) when com-
pared to HS (P < 0.001) and PBT (P< 0.01) (Figure 4F). The
paired analysis have shown significant differences of
apoptotic-effector CD8+ T cells between BG and LbAg in
PDT (BG, 21.2 ± 0.9; LbAg, 28.1 ± 1.5; P < 0.001) and PAT
(BG, 9.6 ± 1; LbAg, 12.3 ± 1.1; P < 0.05) (Figure 4I and J, re-
spectively), while no significant difference was observed in
HS (BG, 1.7 ± 0.4; LbAg, 3 ± 1.1) and PBT (BG, 3.2 ± 0.7;
LbAg, 3.8 ± 0.7) (Figure 4G and Figure 4H, respectively).
Correlation analysis of effector and apoptotic-effector
CD8+ T lymphocytes with lesion size
Taking account the relationship between clinical features
and immune response in CL, we correlated the frequencies
of effector and apoptotic-effector CD8+ T lymphocytes with
lesion size. Results showed an inverse correlation between
frequencies of effector CD8+ T lymphocytes and lesion size
in PDT (r =−0.79; P < 0.001) as well as in PAT (r =−0.79;
P < 0.01). The lower the frequency of effector CD8+ T cells,
the larger the size of lesion (Figure 5B and C, respectively).
In contrary, no statistical correlation was observed between
the frequencies of effector CD8+ T lymphocytes and lesion
size in PBT (Figure 5A). These results suggest that a greater
induction of effector CD8+ T cells after the beginning of
treatment would be associated with small lesions, less
inflammatory process and minor tissue destruction. Correl-
ation analyses between lesion size and antigen-specific
CD8+ T cell were done but no statistically significant result
could be observed (data not shown).
Figure 4 In vitro analysis of effector (A – E) and apoptotic-effector (F - J) CD8+ T-lymphocyte frequencies. (A and F): comparison among the
percentages of Leishmania braziliensis antigen (LbAg)-stimulated cells from HS - healthy subjects (n = 8); PBT – patients before treatment (n = 8);
PDT - patients during treatment (n = 12); and PAT - patients after treatment (n = 6). Statistical analyses were performed by Mann Whitney Test and the
bars represent the mean ± standard error. (B, C, D, E, G, H, I, J): comparison between antigen-stimulated (Lb-Ag) and nonstimulated cells (BG –
background) from HS; PBT; PDT and PAT, respectively. Solid lines connect the results for the same individual. Statistical analyses were performed by
paired, nonparametric Wilcoxon test. Results were considered significant with P < 0.05. *(P < 0.05) **(P < 0.01) ***(P < 0.001).
Figure 5 Clinical characteristics correlated with immunological parameters from cutaneous leishmaniasis patients. Correlation between
the percentage of effector CD8+ T-lymphocytes (A, B, C) and apoptotic-effector CD8+ T-lymphocytes (D, E, F) with diameter of lesion (mm).
(A, D) PBT - patients before treatment (n = 8); (B, E) PDT – patients during treatment (n = 14); (C, F) PAT - patients after treatment (n = 11).
The graphics show fit lines with confidence curves. Statistical analyses were performed by Spearman’s correlation test. Results were considered
significant with P < 0.05.
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apoptotic-total CD8+ Tcells in lesions of patients with active
CL compared with patients evolved to spontaneous cure [7].
Hence, became noteworthy to correlate the frequencies of
circulating-apoptotic-effector CD8+ T cells to lesion sizes in
order to identify a T cell subset implicated either protective
or deleterious role during the treatment or after clinical cure
of CL. It was observed a positive correlation between higher
frequencies of apoptotic-effector CD8+ T cells and larger le-
sion areas in PDT (r = 0.62; P< 0.05) (Figure 5E), although
there were no correlation between these parameters in PBT
and in PAT (Figure 5D and C, respectively).
Discussion
The host immune response to Leishmania is mainly medi-
ated by T cells [28]. The study of immunopathogenesis in
human CL has been based on the determination of the fre-
quency of CD4+ and CD8+ T lymphocytes and cytokine
production [13,27,29]. Earlier observations from our group
have shown that CD8+ T lymphocytes have a role in the
cure process in CL patients [7,8,10,27,30] and other reports
reinforces this hypothesis [14,31]. Conversely, some authors
have associated the CD8+ T lymphocytes to tissue injury in
CL [15] and in mucocutaneous leishmaniasis [11,12]. It is
important to note that, in all of these reports, patients were
evaluated before and after antimonial therapy not taking
into account the immunological events that happen during
treatment. In order to assess the characteristics of the im-
mune response involved in the healing process of CL pa-
tients, it is of utmost importance the evaluation of patients
during antimonial therapy. Our results showed important
differences in the CD8+ T-cell frequencies, characterizing
early and final phases of clinical cure, which seems to be
linked to antimonial therapy.
The frequency of apoptotic CD8+ T cells in HS is in ac-
cordance to the normal apoptotic rate (1–4%) as reported
elsewhere [32]. Because PDT showed higher frequencies
of apoptotic CD8+ T cells than PBT and HS, we suggest
that apoptosis of these cells could be related to the begin-
ning of therapy. The highest frequency of apoptotic CD8+
T lymphocytes observed during the antimonial treatment
could be associated to lower rate of total CD8+ T cells in
PDT, suggesting an association between apoptosis and a
down-modulation of the total CD8+ T cells. It is in accord-
ance with a previous report of our group, which have
shown that high rates of apoptotic-total CD8+ T cells was
related to active disease, while a lower frequency of
apoptotic-total CD8+ T cells is related to spontaneous cure
[7]. Brelaz et al. [27] related the key role of CD8+ T cells in
the process of healing with a significantly higher propor-
tion of circulating CD8+ T lymphocytes in spontaneously
healed patients when compared to patients before treat-
ment. Elevated frequencies of total CD8+ T cells in PAT
compared to PDT, may represent a tendency of these cellsto reestablish levels of normality at the end of treatment
and could be associated to clinical cure.
We observed an increase of apoptotic-total CD8+ T cells
and a decrease of total CD8+ T-cell frequencies in LbAg-
stimulated cultures with cells from PDT as well as from
PBT. Inversely we observed an increase of total CD8+ T-cell
frequencies in LbAg-stimulated cultures with cells from
PAT, showing that at the end of treatment, total CD8+ T
lymphocytes could expand in response to LbAg. Based in
these findings we may hypothesize that the high rates of
apoptosis observed in ex vivo total CD8+ T cells from PDT
could be triggered by expressive amount of circulating anti-
gen derived from parasite destruction caused by the
antimony.
The high frequency of LbAg-reactive total CD8+ T
lymphocytes observed after therapy corroborates data
found by Da-Cruz et al. [10,23] who suggested that the
increased levels of these cells at the end of treatment
would be associated with resolution of lesion. It is worth
to note that these studies compared patients before and
after treatment and there was a need to supplement this
information, evaluating patients during treatment. So,
the increased levels of LbAg-reactive total CD8+ T lym-
phocytes observed at the end of therapy indicate that
probably an expansion of this cell population was not
perceived at early phases of healing process. It is in ac-
cordance with others [33,34] who reported a later devel-
opment of an efficient immune response, i.e., when there
is a balanced response with control of parasite replica-
tion without tissue injury.
Despite the knowledge about the key role of CD8+ T
lymphocytes in the immune response, the evaluation of ef-
fector CD8+ T-cell subset became an imperative approach
for better understanding the specific role of these cells, in
healing process in patients under treatment [19,20,35]. Be-
sides, the relationship between frequencies of effector
CD8+ T cells and the different stages of treatment is un-
known. Taking into account that effector CD8+ T lympho-
cytes represent 10 to 40% of total-circulating CD8+ T cells
and this pool includes a variety of functionally distinct
subpopulations, an analysis of effector population can pro-
vide information about some functional characteristics of
this subset, which would be imperceptible when the ana-
lysis of total CD8+ T lymphocytes was performed.
Concerning ex vivo analysis of effector CD8+ T cell, the
highest percentage observed in PDT seems to indicate a
greater induction of this subset during the treatment. Con-
sidering that Glucantime® is a leishmanicidal drug, a higher
amount of circulating antigen during treatment might in-
duce effector CD8+ T lymphocytes and explain the higher
frequency of these cells in PDT. Some reports corroborates
this statement, as demonstrated by Meymandi et al. [36]
where clearly showed that, at their histological findings,
there was a reduction in aggregations of histiocytes,
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creased numbers of CD3+ T cells in response to combin-
ing antimonial treatment. In another study there was an
increase in the percentage of CD8+ T cells in peripheral
blood from patients with leishmaniasis under treatment
with meglumine antimoniate [37]. Moreover, the lower
frequency of CD8+ T cells observed in PAT may be related
to a reduced antigenic stimulation, which could depict
what is happening in vivo after clinical cure.
Because effector CD8+ T lymphocytes from PDT and
PAT expanded in response to LbAg while PBT did not,
our study indicated that antimonial treatment might not
influence the involvement of effector CD8+ T lymphocytes
in the antigen-specific immune response to parasite.
Apoptosis is a physiological process of immune re-
sponses, however this phenomenon of death can also be a
modulating factor of immunopathogenesis of some disor-
ders such as Dengue, Chagas’ disease and AIDS [21,31,32].
In the present report, high apoptosis rates observed in
LbAg-stimulated effector CD8+ T cells in PDT point to
the occurrence of activation-induced cell death (AICD),
suggesting that this death phenomenon may be happening
in vivo during treatment [33]. Although PAT showed low
frequencies of effector CD8+ T lymphocytes, when com-
pared to PDT, the small rates of apoptotic-effector CD8+
T lymphocytes seem to favor to clinical cure. Moreover, in
parasitic infections the cross-talk between apoptosis of T
lymphocytes and cytokine production was associated to a
deleterious role of this death phenomenon [26].
Some authors considered that the severity of disease
could be characterized by lesion size, which is considered
as the most significant clinical feature in CL [38]. Herein,
we showed that the smaller the size of lesion, the greater
the frequency of effector CD8+ T lymphocytes in PDT and
PAT. Some authors [34] reported that the size of lesion
found in patients evaluated before therapy was directly re-
lated to activated T lymphocytes. Thus, we may postulate
that after the beginning of antimonial therapy there is a
greater induction of effector CD8+ T cells, which is in-
versely proportional to the lesion size, suggesting that a
small frequency of effector CD8+ T lymphocytes can favor
to the tissue damage. Agreeing this data, we showed that
the greater the size of lesion, the higher the frequency of
apoptotic-effector CD8+ T lymphocytes in PDT, suggest-
ing a deleterious role of this death phenomenon. This
observation corroborates with our previous report [7]
where we observed that patients evolved to spontaneous
cure were associated to small frequencies of apoptotic
CD8+ T lymphocytes. This data emphasize the protective
role of CD8+ T cells considering the severity of lesions.
Further studies are underway to determine what func-
tional characteristics these effector cells have, since they
can present cytotoxic and/or pro-inflammatory-cytokine-
producer profiles.Conclusions
Taking together, our results showed an evident expansion
of effector CD8+ T lymphocytes in response to LbAg,
more pronounced in PDT. Changes in effector CD8+ T–
lymphocyte frequencies, during and after treatment, seem
to represent a critical stage to generate an efficient im-
mune response and suggest that these cells would be
evolved in the triggering or in the resolution of lesion,
when under the influence of therapy. Although this work
do not define the effective role of CD8+ T cells in the CL
immunopathogenesis, our findings put forth the notion
that the evolution to cure induced by antimonial therapy
implicate the effector CD8+ T lymphocytes. Moreover, our
results emphasize the protective role of CD8+ T cells con-
sidering the severity of lesions. Further studies are under-
way to determine what functional characteristics these
effector cells have, since they can present cytotoxic and/or
pro-inflammatory-cytokine-producer profiles. This new
approach of evaluating patients during treatment proved
to be very important for understanding the healing
process. Furthermore, this report might be used as a basis
for further investigations concerning antimonial therapy
and to guide vaccine investigations based on the develop-
ment of an effective cellular immune response that regu-
lates tissue damage in human cutaneous leishmaniasis.
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